Gossamer Bio (GOSS) shares are in focus after the company detailed plans to submit an NDA for seralutinib in pulmonary ...
Hosted on MSN
Gossamer Bio Reports Q3 2025 Results and Updates
Gossamer Bio ( (GOSS)) has released its Q3 earnings. Here is a breakdown of the information Gossamer Bio presented to its investors. Gossamer Bio is a late-stage clinical biopharmaceutical company ...
The MarketWatch News Department was not involved in the creation of this content. - Seralutinib demonstrated a placebo-adjusted improvement in Six-Minute Walk Distance (6MWD) of +13.3 meters at Week ...
Gossamer Bio, Inc. (Nasdaq: GOSS) (the "Company" or "Gossamer"), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of ...
Gossamer Bio has experienced numerous ups and downs over the years, including a clinical setback and significant staff reductions. Now, as it pursues potential approval for a heart drug, the company ...
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of ...
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of ...
- Primary endpoint of asthma worsening not met in LEDA Study, however consistent numeric reductions ranging from 32-35% observed across all three GB001 groups - - Statistically significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results